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Case report 
Combining different drugs is a common clinical practice, also for treating somatic diseases in 
psychiatric patients. Pharmacodynamic or pharmacokinetic drug-drug interactions can thereby 
lead to desired effects, attenuated effects, undesired harmful effects or even to serious adverse 
reactions. Treatment with several drugs enhances the risk of adverse drug reactions (ADR) 
and drug-drug interactions. The probability of interactions increases with the number of 
applied drugs. Even in complex clinical cases, valid interaction checks are still difficult, 
especially to assess whether an indicated potential interaction risk is clinically relevant or not.  
The addition of the beta-lactam antibiotic meropenem (MER) for antimicrobial chemotherapy 
to an ongoing therapy with valproic acid (VPA) leads to a well-known decrease of VPA 
serum concentrations [1, 2]. Largely unknown is the influence of this pharmacokinetic 
interaction on a concurrent treatment with the second generation antipsychotic risperidone 
(RIS). We therefore show a clinically complex case where the interaction between VPA, 
MER and RIS led to unexpected effects. 
Mr. A is a 43-year-old inpatient diagnosed with a multiple drug use dependence syndrome (ICD-10: 
F19.2) and a paranoid schizophrenia (ICD-10: F20.0). He was treated successfully with a combination 
of VPA 1,800 mg and RIS 4 mg per day with a stable psychopathology and no signs of acute 
psychosis in the sense of missing positive symptoms such as hallucinations, delusions or bizarre 
behavior. Due to multiple bilateral phlegmons of the forearms with bone involvement in the course of 
an ongoing intravenous drug abuse, he had to undergo plastic surgery with overlap surgery of both 
forearms. MER was added at a daily dose of 3,000 mg because of infections of the skin transplants. 
Therapeutic drug monitoring (TDM) of VPA and RIS was performed as part of an individualized 
treatment optimization. Drug concentrations were measured once a week as trough levels under steady 
state conditions. According to the metabolic ratio between risperidone (RIS) and its active metabolite 
9-OH risperidone (9-OH-RIS) with much higher levels for RIS than for 9-OH-RIS (mean RIS/9-OH-
RIS ratio of 5.3, SD 2.0, see table. 1), it was assumed that the patient was phenotypically a cytochrome 
P450 2D6 (CYP2D6) poor metabolizer (PM). Genotyping of cytochrome P450 2D6, 2C9 and 2C19 
was performed to complete the clinical diagnostic.  
Due to stable clinical conditions with regard to the psychosis and serum levels of the active moiety 
(RIS + 9-OH-RIS) reaching the upper value of the therapeutic reference range (20-60 µg/l, [3], the 
administered daily dose of RIS was reduced from 4 mg to 2 mg before the start of the antimicrobial 
chemotherapy with MER (see table. 1). The mean concentration-by-dose ratio (C/D) for the active 
moiety (calculated as serum concentration divided by the applied dose) was 15.3 (SD 5.2) during this 
first period. The daily dose of VPA remained unchanged. After starting the antimicrobial 
chemotherapy, VPA mean serum concentrations decreased dramatically (minus 83 %) from 37 µg/mL 
(SD 6) to 6 µg/mL (SD 0.6).  
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Despite a reduction of the prescribed daily dose of risperidone from 4 to 2 mg, the serum 
concentration of RIS decreased only by 31 percent after adding MER (mean serum 
concentration: 50 ng/ml, SD 15 ng/ml before, 34 ng/ml, SD 8 ng/ml after addition of MER). 
Mean serum concentrations of the metabolite 9-OH-RIS decreased in an expected range, 
namely by 54% (12 ng/mL, SD 6 ng/ml; after adding MER: mean 5 ng/mL, SD 2 ng/ml).  
‚place tab. 1 about here‘ 
 
Interestingly, serum levels of RIS and 9-OH-RIS changed differentially after the addition of 
MER: the concentration-by-dose ratio (C/D, drug concentration divided by daily dose) for 
RIS increased from 12.4 to 17.1 indicating a lower clearance of RIS while C/D for 9-OH-RIS 
slightly decreased (from 2.9 to 2.7). C/D for the active moiety increased from 15.3 to 20.0 
(see table. 1 and fig. 1.) After termination of the antimicrobial chemotherapy, the C/D ratio 
for RIS, and active moiety decreased again. The ratio RIS/9-OH-RIS temporarily increased 
from 5.0 (SD 1.92) to 6.6 (SD 1.19) under MER co-medication and decreased again to 5.5 
(SD 2.80) after ending the MER therapy. Cytochrome P450 genotyping showed a poor 
metabolizer (PM) status (*4/*4) for CYP2D6, an extensive metabolizer status (*1/*1) for 2C9 
and a rapid metabolizer status (*1/*17) for 2C19. 
‚place fig. 1 about here‘ 
 
Discussion 
Several mechanisms are hypothesized to explain the decrease of VPA after the addition of carbapenem 
antibiotics, such as meropenem. They include an effect at the intestinal absorption site, the liver site 
(decrease of the uridine 5’-diphospho-glucuronic acid (UDPGA) level by carbapenem antibiotics, a 
direct activation of uridine 5’diphospho-glucuronosyltransferase (UGT) by carbapenem antibiotics, or 
an inhibition of β-glucuronidase) and/or at the distribution site of VPA in blood (for more details, see 
[4]). The metabolism of both VPA and meropenem is independent from CYP2D6 activity while RIS is 
mainly metabolized via CYP2D6 to the active metabolite 9-OH-RIS. This pharmacokinetic interaction 
between 3 drugs is complexified by the CYP2D6 poor metabolizer status. Because homozygotes for 
the null alleles of CYP2D6 such as *4 do not have any functional CYP2D6 protein, it was not 
expected that the preexisting high ratio of RIS/9-OH-RIS, indicating a CYP2D6 poor metabolizer 
status, was influenced by MER. However, after starting MER, not only VPA serum levels decreased 
but also serum levels of the active moiety of RIS increased, an effect mostly driven by a higher 
concentration by dose ratio (C/D) for RIS despite a small decrease of 9-OH-RIS concentration by dose 
ratio suggesting a reduced formation of 9-OH-RIS from RIS. Of note, although CYP2D6 is the main 
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isoform responsible of RIS metabolism, a contribution of CYP3A to RIS metabolism has also been 
suggested by several interaction studies with CYP3A inducers [5, 6], or inhibitors [7, 8].  
We therefore hypothesize that the observed inhibition of RIS metabolism in a CYP2D6 poor 
metabolizer is due to the blockade of secondary metabolic pathways, mediated by CYP3A and/or 
other isoforms. An increasing importance of CYP3A4 in the metabolism of clozapine, a drug mainly 
metabolized by CYP1A2, has thus been demonstrated in patients with blocked CYP1A2 activity [9]. 
Concerning risperidone, in CYP2D6 poor metabolizers, CYP3A could be important for the production 
of 9-hydroxy risperidone [10] and a case study suggested that CYP2D6 genotype may influence 
susceptibility to a clinically important interaction with carbamazepine, a CYP3A inducer [11]. If true, 
a weaker inhibitory effect of MER on RIS pharmacokinetics would probably be observed in a 
CYP2D6 extensive metabolizer, if observed at all. We can however not exclude that the observed 
interaction is mediated by changes in VPA serum concentrations, in that case the mechanism 
remaining unclear. Luckily, due to the relatively short period of decreased VPA serum concentrations, 
no changes in psychopathology were observable. VPA was administered for affective control and 
against impulsivity but decreasing VPA levels did not lead to a reoccurrence of any of those 
symptoms.  
Finally, the present complex case of pharmacokinetic interaction between 3 drugs, possibly also 
depending on the metabolic status of the patient, underscores the clinical usefulness of TDM for 
treatment optimization. Luckily, during the entire duration of the inpatient treatment, before, during 
and after the antimicrobial treatment with meropenem and although the daily dose of risperidone was 
halved, the clinical condition of the patient was stable and no psychotic symptoms recurred.  
6  
 Table legends 
Tab. 1: Daily doses of risperidone (RIS) and valproic acid (VPA), and serum levels of RIS, 9-OH-RIS 
and VPA before, during and after a concomitant treatment with meropenem (MER) 
 
Figure legends 
Fig. 1: Risperidone, 9-OH-risperidone and valproic acid (VPA) serum-levels before, during and after 
concomitant medication with meropenem. Serum levels of RIS and 9-OH-RIS in ng/mL, VPA serum-
levels in µg/mL. Daily dose of RIS was reduced from 4 mg to 2 mg. Meropenem treatment started at 
week 4 and ended with week 9. 
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  risperidone concomitant treatment with MER risperidone 
week 1 2 3 mean 4 5 6 7 8 mean 9 10 11 12 mean 
DD risperidone 4 4 4 4 2 2 2 2 2 2 2 2 2 2 2 
RIS 35.5 47.4 66.0 49.6 22.4 43.3 29.1 38.2 38.3 34.3 23.5 24.8 21.5 20.9 22.7 
C/D (RIS)  8.9 11.9 16.5 12.4 11.2 21.7 14.6 19.1 19.2 17.1 11.8 12.4 10.8 10.5 11.3 
9-OH-RIS  4.9 14.1 16.0 11.7 3.6 5.9 3.9 5.2 8.1 5.3 5.6 2.6 7.0 4.0 4.8 
C/D (9-OH-RIS)  1.2 3.5 4.0 2.9 1.8 3.0 2.0 2.6 4.0 2.7 2.8 1.3 3.5 2.0 2.4 
RIS + 9-OH-RIS, AM 40.4 61.5 82 61.3 26 49.2 33 43.4 46.4 39.6 29.1 27.4 28.5 24.9 27.5 
C/D AM 10.1 15.4 20.5 15.3 13 24.6 16.5 21.7 23.2 19.8 14.6 13.7 14.3 12.5 13.7 
Ratio RIS/9-OH-RIS 7.2 3.7 4.1 5.0 6.2 7.3 7.5 7.4 4.7 6.6 4.2 9.5 3.1 5.2 5.5 
DD VPA 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 1,800 
VPA  30.1 40.3 40.5 37.0 6.0 5.4 5.2 7.3 7.1 6.2 54.4 67.4 69.4 89 70.1 
DD – daily dose, value in mg; C/D – concentration by dose ratio, values given in (ng/mL)/(mg/day); values for RIS, 9-OH-RIS and AM, active moiety = RIS + 9-OH-RIS, are given in ng/mL; 
values for valproate, VPA, are given in µg/mL. 
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